These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

148 related items for PubMed ID: 6124759

  • 1. Double-blind controlled trial of immunosuppression in the treatment of multiple sclerosis: final report.
    Mertin J, Rudge P, Kremer M, Healey MJ, Knight SC, Compston A, Batchelor JR, Thompson EJ, Halliday AM, Denman M, Medawar PB.
    Lancet; 1982 Aug 14; 2(8294):351-4. PubMed ID: 6124759
    [Abstract] [Full Text] [Related]

  • 2. Double-blind, controlled trial of immunosuppression in treatment of multiple sclerosis.
    Mertin J, Knight SC, Rudge P, Thompson EJ, Healy MJ.
    Lancet; 1980 Nov 01; 2(8201):949-51. PubMed ID: 6107592
    [Abstract] [Full Text] [Related]

  • 3. Histocompatibility antigens in multiple sclerosis patients participating in a multicentre trial of azathioprine. British & Dutch Multiple Sclerosis Azathioprine Trial Group.
    J Neurol Neurosurg Psychiatry; 1988 Mar 01; 51(3):412-5. PubMed ID: 3283297
    [Abstract] [Full Text] [Related]

  • 4. Mitoxantrone: a review of its use in multiple sclerosis.
    Scott LJ, Figgitt DP.
    CNS Drugs; 2004 Mar 01; 18(6):379-96. PubMed ID: 15089110
    [Abstract] [Full Text] [Related]

  • 5. Double-masked trial of azathioprine in multiple sclerosis. British and Dutch Multiple Sclerosis Azathioprine Trial Group.
    Lancet; 1988 Jul 23; 2(8604):179-83. PubMed ID: 2899660
    [Abstract] [Full Text] [Related]

  • 6. Intensive immunosuppression in the treatment of multiple sclerosis.
    Ring J, Seifert J, Lob G, Coulin K, Angstwurm H, Frick E, Brass B, Mertin J, Backmund H, Brendel W.
    Lancet; 1974 Nov 09; 2(7889):1093-6. PubMed ID: 4139403
    [No Abstract] [Full Text] [Related]

  • 7. Immunosuppressive effects of isoprinosine in man: a comparison to chlorambucil effects in multiple sclerosis.
    Pompidou A, Rancurel G, Delsaux MC, Meunier C, Telvi L, Cour V, Buge A.
    Cancer Detect Prev Suppl; 1987 Nov 09; 1():377-83. PubMed ID: 2446758
    [Abstract] [Full Text] [Related]

  • 8. [Treatment of progressive and severe forms of multiple sclerosis using a combination of antilymphocyte serum, azathioprine and prednisone. Clinical and biological results. Comparison with a control group treated with azathioprine and prednisone only. 4-year follow-up].
    Lhermitte F, Marteau R, de Saxcé H.
    Rev Neurol (Paris); 1987 Nov 09; 143(2):98-107. PubMed ID: 3299618
    [Abstract] [Full Text] [Related]

  • 9. Double blind controlled randomized study on azathioprine efficacy in multiple sclerosis. Preliminary results.
    Milanese C, La Mantia L, Salmaggi A, Campi A, Bortolami C, Tajoli L, Nespolo A, Corridori F.
    Ital J Neurol Sci; 1988 Feb 09; 9(1):53-7. PubMed ID: 3281916
    [Abstract] [Full Text] [Related]

  • 10. Clinical experience with azathioprine: the pros.
    Ellison GW, Myers LW, Mickey MR, Graves MC, Tourtellotte WW, Nuwer MR.
    Neurology; 1988 Jul 09; 38(7 Suppl 2):20-3. PubMed ID: 3290709
    [Abstract] [Full Text] [Related]

  • 11. Management of worsening multiple sclerosis with mitoxantrone: a review.
    Fox EJ.
    Clin Ther; 2006 Apr 09; 28(4):461-74. PubMed ID: 16750460
    [Abstract] [Full Text] [Related]

  • 12. A randomized double-blind trial of prednisolone alone or with azathioprine in myasthenia gravis. Myasthenia Gravis Study Group.
    Palace J, Newsom-Davis J, Lecky B.
    Neurology; 1998 Jun 09; 50(6):1778-83. PubMed ID: 9633727
    [Abstract] [Full Text] [Related]

  • 13. Intensive immunosuppression in patients with disseminated sclerosis. III. Lymphocyte response in vitro.
    Knight SC, Lance EM, Abbosh J, Munro A, O'Brien J.
    Clin Exp Immunol; 1975 Jul 09; 21(1):23-31. PubMed ID: 1181076
    [Abstract] [Full Text] [Related]

  • 14. [Immunosuppressive treatment im multiple sclerosis].
    Mertin J.
    Fortschr Med; 1980 Oct 02; 98(37):1431-6. PubMed ID: 6253370
    [Abstract] [Full Text] [Related]

  • 15. A placebo-controlled, randomized, double-masked, variable dosage, clinical trial of azathioprine with and without methylprednisolone in multiple sclerosis.
    Ellison GW, Myers LW, Mickey MR, Graves MC, Tourtellotte WW, Syndulko K, Holevoet-Howson MI, Lerner CD, Frane MV, Pettler-Jennings P.
    Neurology; 1989 Aug 02; 39(8):1018-26. PubMed ID: 2668784
    [Abstract] [Full Text] [Related]

  • 16. A controlled double blind study of azathioprine in the management of Crohn's disease.
    Candy S, Wright J, Gerber M, Adams G, Gerig M, Goodman R.
    Gut; 1995 Nov 02; 37(5):674-8. PubMed ID: 8549944
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial.
    Calabresi PA, Radue EW, Goodin D, Jeffery D, Rammohan KW, Reder AT, Vollmer T, Agius MA, Kappos L, Stites T, Li B, Cappiello L, von Rosenstiel P, Lublin FD.
    Lancet Neurol; 2014 Jun 02; 13(6):545-56. PubMed ID: 24685276
    [Abstract] [Full Text] [Related]

  • 19. Independent risk factors predicting acute graft rejection in cardiac transplant recipients treated by triple drug immunosuppression.
    Laufer G, Miholic J, Laczkovics A, Wollenek G, Holzinger C, Hajek-Rosenmeier A, Wuzl G, Schreiner W, Buxbaum P, Wolner E.
    J Thorac Cardiovasc Surg; 1989 Dec 02; 98(6):1113-21. PubMed ID: 2586129
    [Abstract] [Full Text] [Related]

  • 20. Azathioprine in multiple sclerosis: the cons.
    Silberberg DH.
    Neurology; 1988 Jul 02; 38(7 Suppl 2):24-7. PubMed ID: 3290710
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.